Welcome to our dedicated page for Preferred Commer news (Ticker: CELV), a resource for investors and traders seeking the latest updates and insights on Preferred Commer stock.
Cellev8 Nutrition Inc (CELV) delivers innovative SOD-based supplements through advanced delivery systems designed to optimize cellular health. This news hub provides investors and industry stakeholders with essential updates on scientific advancements, regulatory milestones, and strategic developments.
Access timely announcements including product launches, clinical research findings, and partnership agreements. Our curated collection features press releases detailing advancements in antioxidant formulations, manufacturing innovations, and market expansion initiatives within the nutraceutical sector.
Key updates cover patent progress, quality assurance protocols, and collaborations with sports nutrition partners. Bookmark this page for verified information on CELV's progress in transforming cellular health research into consumer-ready solutions.
Cellev8 Nutrition (OTC PINK:CELV) has announced a strategic partnership with NFL Hall of Famer Andre Reed, launched during the Super Bowl. The company specializes in advanced natural supplements featuring Superoxide Dismutase (SOD), utilizing a patent-pending soluble fiber-enhanced gummy technology that delivers approximately 140+ units of SOD2 daily.
The partnership launch generated significant exposure, with Reed introducing Cellev8 to influential players and Hall of Famers. The company's product line includes Inflammation & Recovery Gummies, SlimCell Gummies, and the upcoming Elev8 sports nutrition product. Currently, over 40 professional and collegiate teams are purchasing Cellev8's products.
The company operates in the growing wellness supplements market, which is projected to reach $568.75 billion by 2034, with the global gummy supplements market expected to hit $15.88 billion by 2030.
Cellev8 Nutrition has announced an exclusive partnership with NFL Hall of Famer Andre Reed, set to launch at the Super Bowl. The multi-year collaboration aims to promote the benefits of Superoxide Dismutase (SOD) through Cellev8's nutritional products.
The company offers three key products: Slim Cell for weight management and GLP1 support, Focus and Memory for cognitive enhancement, and Inflammation and Recovery for reducing inflammation. These products utilize a patent-pending delivery system that ensures ingredients reach their intended destinations in the body.
The products are designed to optimize cellular function, enhance SOD production, accelerate recovery, reduce oxidative stress, boost energy production, support detoxification, improve sleep quality, and promote long-term wellness. Reed reported personal benefits including reduced headaches, improved joint mobility, and overall body and brain revitalization.
Cellev8 Nutrition Inc (OTC PINK:CELV) has filed two patents at the US Trademark and Patent Office for its innovative supplement delivery systems. The patents focus on enhancing the transport of Superoxide Dismutase (SOD) and other ingredients throughout the body. The patent-pending formulations aim to improve absorption and utilization of key ingredients, particularly in their SOD formulations.
The company's delivery mechanisms have demonstrated effectiveness across thousands of users, targeting oxidative stress reduction and cellular protection. The technology will be applied across Cellev8's product range, including inflammation and recovery, focus and memory, and GLP1 support gummies. The company currently serves thousands of customers, including over 40 professional and collegiate athletic teams, and maintains partnerships with FDA-certified companies.
Cellev8 Nutrition has launched SlimCell™, a revolutionary gummy supplement designed to support post-GLP-1 weight management. The product features clinically proven ingredients including SOD B® and Morosil, along with soluble fibers. Clinical studies showed significant results: 9.5% cellulite reduction in 28 days, 23% decrease in gluteal folds, and 28% reduction in femoral folds after 3 months. The patent-pending formulation works by reducing oxidative stress, enhancing GLP-1 signaling, and providing cellular protection. The product is positioned in the $142 billion weight loss industry, targeting both GLP-1 medication users and individuals seeking natural weight management solutions.
Cellev8 Nutrition (OTC Pink:CELV) and Vivos Therapeutics announced a strategic joint marketing venture to address obstructive sleep apnea (OSA) and oxidative stress. The collaboration combines Vivos' FDA-cleared oral medical devices for treating OSA with Cellev8's SOD2-based nutraceutical gummies.
The venture targets a significant market, with an estimated 80 million American adults and 10 million children affected by sleep apnea, with up to 80% undiagnosed. The partnership aims to provide a comprehensive solution through Cellev8's nutraceutical products, which have shown efficacy in reducing oxidative stress, inflammation, and improving metabolic health in clinical trials.
The collaboration offers a complementary approach where Vivos devices restore airways while Cellev8's products support bodily rejuvenation and recovery from OSA-related damage.
Cellev8 Nutrition Inc (OTC PINK:CELV) has issued a statement retracting previous announcements about entering the CBD/Cannabis industry, clarifying that no agreements were finalized in this sector. The company has instead positioned itself as a pioneer in Superoxide Dismutase (SOD) based supplements, becoming the first to deliver SOD in gummy form commercially. The company serves thousands of customers, including over 40 professional and collegiate athletic teams, focusing on products for inflammation, recovery, focus, and memory support.
Cellev8 Nutrition (formerly Preferred Commerce) announces corporate updates and growth initiatives. The company has completed its name change and hired Fox Rothschild for legal matters and Salberg & Co. for auditing. Their patent-pending technology delivers SOD2 through proprietary Fibersol-enhanced gummies, now used by 40 professional and collegiate sports teams, up from 2 at year start.
The company reports successful partnerships with Amazon, Vitacost, and Walmart online, plus marketing agreements with Zyppah and Vivos, potentially reaching nearly 1,000,000 customers. New products include SlimCell™ for weight management and Elev8™ for sports nutrition. The company has added notable experts to its advisory board, including sports nutritionists from major league teams.
Cellev8 and Zyppah have announced a collaborative sales agreement targeting 90 million Americans affected by snoring. The partnership combines Cellev8's SOD-based inflammation and recovery gummies with Zyppah's anti-snoring devices. The global anti-snoring devices market, valued at $1.52 billion in 2022, is projected to reach $2.65 billion by 2030. Undiagnosed sleep apnea costs the U.S. economy approximately $149.6 billion annually. The joint offering will be available starting November 1, 2024, through both companies' websites with specific discount codes and subscription models.
